Description
Kytib™ is a quality assured generic of Inlyta® used as first-line treatment of patients with advanced renal cell carcinoma (RCC) in combination with other medicines. It’s also indicated for the treatment of advanced renal cell carcinoma (RCC) in adult patients who failed 1 prior systemic therapy. It’s produced in a US FDA approved factory in India.
Package Size : 14 Tablets
Active Ingredients : Axitinib
Produced by Hetero Drugs Ltd®